TITLE

Interferon-α/β Receptor as a Prognostic. Marker in Osteosarcoma

AUTHOR(S)
Kubo, Tadahiko; Shimose, Shoji; Matsuo, Toshihiro; Fujimori, Jun; Arihiro, Koji; Ochi, Mitsuo
PUB. DATE
March 2011
SOURCE
Journal of Bone & Joint Surgery, American Volume;3/16/2011, Vol. 93-A Issue 6, p519
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A large-scale randomized trial of adjuvant interferon-α therapy for patients with osteosarcoma has been initiated as a joint protocol by the European and American Osteosarcoma Study Group. Because the expression of functional interferon-α/β receptor is necessary for interferon-a agents to interact with osteosarcoma cells, we examined the expression of interferonα/β receptor in a series of osteosarcoma specimens. Methods: Forty patients with high-grade resectable osteosarcoma, from whom surgical specimens had been obtained at the time of biopsy, were included in this retrospective study. Biopsy specimens were immunohistochemically stained with anti-interferon-a/13 receptor antibodies. Survival was estimated with the Kaplan-Meier method. The Cox proportional hazards model was used for multivariate analysis to determine the independent prognostic factors. Furthermore, we used Holm and Benjamini-Hochberg procedures to adjust for multiple comparisons in setting the level of significance. The median follow-up period was five years and two months (range, four to 195 months). Results: The expression of interferon-a/13 receptor was positive in eighteen (45%) of the forty patients with high-grade osteosarcoma. American Joint Committee on Cancer surgical stage HA, a good histologic response to chemotherapy, and expression of interferon-a/13 receptor correlated significantly with better disease-free survival (p < 0.05). Multivariate analysis showed that interferon-a/13 receptor expression alone retained its power to predict an improved prognosis (p = 0.042). There were no significant variables after corrections for multiple comparisons. Conclusions: lnterferon-a/3 receptor may be a useful marker for assessing tumor prognosis in patients with osteosarcoma and may play an important role in tumor progression. These findings are encouraging and support the ongoing clinical trials of adjuvant interferon-a therapy by the multinational Osteosarcoma Study Group. Our pilot study was based on a small sample size, and larger trials are needed to confirm this finding.
ACCESSION #
59392956

 

Related Articles

  • The Number of Resected Lymph Nodes (nLNs) Combined with Tumor Size as a Prognostic Factor in Patients with Pathologic N0 and Nx Non-Small Cell Lung Cancer. Yang, Miaomiao; Cao, Hongxin; Guo, Xi; Zhang, Tiehong; Hu, Pingping; Du, Jiajun; Liu, Qi // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Background: The prognostic role of the number of resected lymph nodes (nLNs) in pathologic N0 (lymph node negative) and Nx (no lymph node examined) non-small cell lung cancer (NSCLC) patients remains uncertain. Guidelines for optimal nLNs have not been established. In the current study, we...

  • Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. Kakudo, K.; Tang, W.; Ito, Y.; Mori, I.; Nakamura, Y.; Miyauchi, A. // Journal of Clinical Pathology;Oct2004, Vol. 57 Issue 10, p1041 

    Aims: Papillary thyroid carcinoma (FTC) is classified into two subgroups--common type and other histological variants. Correlations between further subgrouping of the common type and patient prognosis are not well documented. Aims: To introduce two novel histological parameters to characterise...

  • Fifteen Years' Experience of the Brazilian Osteosarcoma Treatment Group (BOTG): A Contribution from an Emerging Country. Petrilli, Antonio Sergio; Brunetto, Algemir Lunardi; Cypriano, Monica dos Santos; Ferraro, Alexandre Archanjo; Donato Macedo, Carla Renata Pacheco; Senerchia, Andreza Almeida; Almeida, Maria Teresa; Costa, Cecilia Maria da; Lustosa, Daniel; Borsato, Maria Luiza; Calheiros, Luiz Mario; Barreto, Jose Henrique Silva; Epelman, Sidnei; Carvalho, Eny; Alves, Maria Teresa Seixas; Petrilli, Marcelo de Toledo; Penna, Valter; Pericles, Pedro; de Camargo, Olavo Pires; Garcia-Filho on behalf of th // Journal of Adolescent & Young Adult Oncology;Dec2013, Vol. 2 Issue 4, p145 

    Purpose: Little information is available regarding the tumor features, prognostic factors, and treatment results in children and adolescents and young adults (AYAs) with osteosarcoma diagnosed in developing countries. We reviewed the results of three observational cohorts of osteosarcoma...

  • MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma. GANG HAN; YAN WANG; WENZHI BI; JINPENG JIA; WEI WANG // Experimental & Therapeutic Medicine;2015, Vol. 9 Issue 3, p679 

    MicroRNA-124 (miR-124) has been demonstrated to be downregulated in numerous human malignancies and correlated with tumor progression. However, its expression and clinical significance in osteosarcoma remains unclear. Thus, the aim of the present study was to explore the effects of miR-124 in...

  • Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. Suzuki, Fumitaka; Arase, Yasuji; Suzuki, Yoshiyuki; Akuta, Norio; Sezaki, Hitomi; Seko, Yuya; Kawamura, Yusuke; Hosaka, Tetsuya; Kobayashi, Masahiro; Saito, Satoshi; Ikeda, Kenji; Kobayashi, Mariko; Kumada, Hiromitsu // Journal of Gastroenterology;Jul2012, Vol. 47 Issue 7, p814 

    Background: Few studies have investigated the long-term effects of interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy of and predictors of response to IFN therapy in CHB patients. Methods: We analyzed data for 615 Japanese CHB...

  • Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. Wang, Yan-Na; Shen, Kun-Tang; Ling, Jia-Qian; Gao, Xiao-Dong; Hou, Ying-Yong; Wang, Xue-Fei; Jing Qin; Sun, Yi-Hong; Qin, Xin-Yu // BMC Surgery;2012, Vol. 12 Issue 1, p1 

    Background: Gastric cancer with synchronous liver metastasis remains a clinical treatment challenge. There has been a longstanding debate on the question whether surgical resection could be beneficial to long-term survival. This study is to investigate the effectiveness and prognostic factors of...

  • Clinicopathological study of p-T1aN0M0 non-small-cell lung cancer, as defined in the seventh edition of the TNM classification of malignant tumors Igai, Hitoshi; Matsuura, Natsumi; Tarumi, Shintaro; Chang, Sung Soo; Misaki, Noriyuki; Go, Tetsuhiko; Ishikawa, Shinya; Yokomise, Hiroyasu // European Journal of Cardio-Thoracic Surgery;Jun2011, Vol. 39 Issue 6, p963 

    Abstract: Objective: The seventh edition of the TNM Classification of Malignant Tumours was published in 2009. The present study was conducted to investigate the clinicopathological features of p-T1aN0M0 non-small-cell lung cancer, which is the earliest stage defined in the new tumor, node,...

  • Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. Colavolpe, Cécile; Metellus, Philippe; Mancini, Julien; Barrie, Maryline; Béquet-Boucard, Céline; Figarella-Branger, Dominique; Mundler, Olivier; Chinot, Olivier; Guedj, Eric // Journal of Neuro-Oncology;May2012, Vol. 107 Issue 3, p527 

    The prognostic value of PET with (18F)-fluoro-2-deoxy- d-glucose (FDG) has been shown in high-grade gliomas (HGG), but not compared with consensual prognostic factors. We sought to evaluate the independent predictive value of pre-treatment FDG-PET on overall (OS) and event-free survival (EFS)....

  • Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Kanoun, Salim; Rossi, Cédric; Berriolo-Riedinger, Alina; Dygai-Cochet, Inna; Cochet, Alexandre; Humbert, Olivier; Toubeau, Michel; Ferrant, Emmanuelle; Brunotte, François; Casasnovas, René-Olivier // European Journal of Nuclear Medicine & Molecular Imaging;Sep2014, Vol. 41 Issue 9, p1735 

    Purpose: The presence of a bulky tumour at staging in Hodgkin lymphoma (HL) is a predictor of a poor outcome. The total metabolic tumour volume at baseline (TMTV0) computed on PET may improve the evaluation of tumour burden. To explore the clinical usefulness of TMTV0, we compared the prognostic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics